Jak 1-3 Inhibitors and Tyk-2 Inhibitors in Dermatology: Practical Pearls for the Primary Care Physician

Janus kinase (JAK) inhibitors and tyrosine kinase 2 (TYK2) inhibitors are emerging treatments for inflammatory skin conditions such as atopic dermatitis, plaque psoriasis, alopecia areata, and vitiligo, with several gaining FDA approval. These inhibitors modulate immune responses, showing significant efficacy in clinical trials, particularly for alopecia areata with baricitinib and ritlecitinib, and vitiligo with ruxolitinib. Despite their effectiveness, JAK inhibitors have serious adverse effects, requiring careful patient education and monitoring. Safety profiles are generally reassuring, but precautions are necessary for patients with specific health conditions. Collaboration between dermatologists and primary care physicians is crucial for optimizing patient outcomes, and ongoing research is focused on safety and new applications.